p14ARF is inactivated by deletions/mutations in many cancer types and can suppress cell growth by both p53-dependent and p53-independent mechanisms. To identify novel downstream effectors of p14ARF, we used gene expression profiling as a primary screening tool to select candidates for follow up validation studies using in vitro cell-based assays. Gene expression profiles of a panel of 35 melanoma cell lines with either wild-type (n = 12) or mutant (n = 23) p14ARF were compared to identify genes associated with inactivation of p14ARF. Analysis of the microarray data identified 1,316 probe sets that were significantly (p < 0.01) differentially expressed between the p14ARF wild-type and mutant cell lines. Pathway analysis of these genes showed an overrepresentation of many receptor-mediated signal transduction pathways, e.g. TGFβ, EGF, HGF, PDGF, MAPK, Wnt and integrin pathways. A number of components of these pathways, including FLRT3, RUNX2, MIG-6 and SMURF2 were confirmed as downstream targets of p14ARF using p14ARF-inducible cell lines and RNAi. We propose that regulation of these genes may contribute to melanoma development when p14ARF function is lost. © 2007 Wiley-Liss, Inc.
CITATION STYLE
Packer, L. M., Pavey, S. J., Boyle, G. M., Stark, M. S., Ayub, A. L., Rizos, H., & Hayward, N. K. (2007). Gene expression profiling in melanoma identifies novel downstream effectors of p14ARF. International Journal of Cancer, 121(4), 784–790. https://doi.org/10.1002/ijc.22725
Mendeley helps you to discover research relevant for your work.